Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 18;11(2):251-255.
doi: 10.18240/ijo.2018.02.12. eCollection 2018.

Trabeculectomy with Ologen implant versus mitomycin C in congenital glaucoma secondary to Sturge Weber Syndrome

Thanaa Helmy Mohamed  1 , Abdelrahman Gaber Salman  1 , Riham Fawzy Elshinawy  1
Affiliations

Trabeculectomy with Ologen implant versus mitomycin C in congenital glaucoma secondary to Sturge Weber Syndrome

Thanaa Helmy Mohamed et al. Int J Ophthalmol. .

Abstract

Aim: To compare the efficacy and safety of collagen matrix implant [Ologen (OLO) implant] versus mitomycin C (MMC) with subscleral trabeculectomy (SST) for the surgical treatment of congenital glaucoma (CG) in Sturge-Weber Syndrome (SWS).

Methods: A prospective comparative randomized study of 20 eyes of 16 patients with CG associated with SWS was divided into two groups. The first group (MMC Group) included 10 eyes that were subjected to SST with MMC. The second group (OLO Group) included 10 eyes that were subjected to trabeculectomy with a collagen matrix implant (OLO implant). Postoperative evaluation included intraocular pressure (IOP) level, bleb evaluation, complications, and the need for further medication or surgical intervention.

Results: The mean preoperative IOP was 29±3.16 mm Hg in MMC and 29.8±3.08 mm Hg in OLO eyes. Mean 12-month percentage reduction in IOP was significant in both groups (57.9% and 56.3%). At the end of the 12 postoperative follow-up month, in the MMC Group, 80% of eyes achieved the complete success, 20% of eyes had qualified success with no failed surgery in comparison to OLO Group which 70% of eyes achieved the complete success, 20% of eyes had qualified success with 10% failed surgery. In terms of complications, the MMC Group had a higher rate of complications than the OLO Group in the form of thin polycystic bleb in 6 eyes (60%), blebitis in only one eye (10%) treated with topical antibiotics, shallow anterior chamber in two eyes (20%).

Conclusion: This study proves that the use of a collagen matrix implant yields equally effective results as MMC when combined with trabeculectomy for the treatment of CG in SWS. Furthermore, OLO implantation is safe and has low incidences of complications.

Keywords: Ologen implants; Sturge-Weber Syndrome; congenital glaucoma; mitomycin C; trabeculectomy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Glaucoma associated with SWS.
Figure 2
Figure 2. Surgical details of OLO group
A: OLO implant; B: OLO implant under the conjunctiva.
Figure 3
Figure 3. Graph showing success rate at 12th month.
Figure 4
Figure 4. Post-operative complication
A: Thin polycystic bleb of patient from MMC Group; B: Magnified picture of same patient.
Figure 5
Figure 5. Frequency (%) of postoperative complications.
See this image and copyright information in PMC

References

    1. Comi AM. Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. Neurologist. 2011;17(4):179–184. - PMC - PubMed
    1. Basler L, Sowka J. Sturge-Weber syndrome and glaucoma. Optometry. 2011;82(5):306–309. - PubMed
    1. Javaid U, Ali MH, Jamal S, Butt NH. Pathophysiology, diagnosis, and management of glaucoma associated with Sturge-Weber syndrome. Int Ophthalmol. 2017 - PubMed
    1. Pascual-Castroviejo I, Pascual-Pascual SL, Velazquez-Fragua R, Viaño J. Sturge-Weber syndrome: study of 55 patients. Can J Neurol Sci. 2008;35(3):301–307. - PubMed
    1. Mantelli F, Bruscolini A, La Cava M, Abdolrahimzadeh S, Lambiase A. Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management. Clin Ophthalmol. 2016;10:871–878. - PMC - PubMed

LinkOut - more resources